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ABSTRACT
The progressive nature of type 2 diabetes (T2D)
often results in the need for initiation and
subsequent intensification of insulin treatment
to achieve glycemic control. The aim of this
review is to examine published clinical evidence
that has directly compared two recommended
treatment approaches in patients with T2D: (1) a
‘basal plus’ regimen, whereby 1–2 injections of
prandial insulin are added to basal insulin; or (2)
the use of once- or twice-daily premix insulin
analogs, which contain both basal and prandial
insulin in a single injection. Broadly, the
available evidence suggests that both basal plus
and premix regimens are comparable in terms of
efficacy and safety when used for insulin
initiation in insulin-naı¨ve patients and
intensification in patients who have failed on
basal insulin; instances of greater glycemic
control are observed with premix insulin;
however, these are often accompanied by
increases in hypoglycemia and/or weight
relative to basal plus treatment, and results
should be interpreted within the context of
total insulin doses used. Relatively low
numbers of patients achieved glycemic control
when both regimens were used for insulin
intensification following failure of basal insulin,
suggesting that a full basal–bolus regimen and/or
the use of different treatments is clinically
indicated in certain patients. In summary, the
current review argues that both basal plus and
premix insulin regimens are relatively efficacious
and safe options for patients with T2D during
both insulin initiation in insulin-naı¨ve patients
and intensification in patients who have failed
on basal insulin. This emphasizes the important
role of patient-centered factors in clinical
decision-making.
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INTRODUCTION
Type 2 diabetes (T2D) is a chronic disease that
results in a majority of patients requiring
insulin treatment due to the progressive
decline in pancreatic b-cell function [1].
Clinical guidelines in many countries,
including those of the Australian Diabetes
Society (ADS) and International Diabetes
Federation (IDF), suggest that insulin can be
initiated with either a long-acting basal insulin
(e.g., insulin glargine, insulin detemir, insulin
degludec) administered once daily (OD), or
premix insulin administered OD or twice daily
(BID), when lifestyle changes and treatment
with glycemic-lowering, oral antidiabetic drugs
(OADs) (usually in combination therapy) are no
longer sufficient to help the patient achieve
recommended glycemic targets [2, 3].
In clinical practice, insulin switching and/or
intensification following initiation with basal
insulin is commonly required. For example,
following 1 year of insulin detemir OD
treatment in the Novo Nordisk-sponsored ‘4T’
trial, only 8.1% of patients achieved glycemic
control from a baseline glycated hemoglobin
(HbA1c) of 8.5% [4]. Switching and/or
intensification is often required to reduce
postprandial plasma glucose (PPG) excursions;
basal-only regimens are unlikely to cover these
instances of postprandial hyperglycemia, and
closer attention to PPG is usually necessary to
achieve tight glycemic targets [5]. Additionally,
control of PPG may be an important factor to
reduce diabetes-related cardiovascular
complications and mortality [6, 7]. For
insulin-treated patients with T2D who require
intensification, clinical guidelines recommend
to: (1) continue with basal insulin OD and add
rapid-acting prandial insulin in a ‘stepwise’
manner, up to three-times daily (TID), i.e., a
full basal–bolus regimen; or (2) intensify or
transfer to premix insulin BID [2, 3].
Premix insulin analogs combine a fixed ratio
of rapid-acting and protaminated insulin, which
provide both prandial and basal components in a
single formulation and are generally
administered BID [8]. Common premix insulins
include biphasic insulin aspart 30/70 (e.g.,
NovoMix 30; Novo Nordisk A/S, Bagsvaerd,
Denmark), which contains 30% rapid-acting
insulin aspart and 70% intermediate-acting
protaminated insulin aspart, and insulin lispro
25/75 (e.g., Humalog Mix25; Eli Lilly and
Company, Indianapolis, Indiana, United States),
which contains 25% insulin lispro injection and
75% protaminated insulin lispro. Newer premix
analogs such as insulin degludec/insulin aspart
(Ryzodeg; Novo Nordisk A/S, Bagsvaerd,
Denmark) are also gaining popularity in clinical
practice. It is thought that up to 40% of patients
with T2D currently use premix insulin as part of
their treatment, and a number of guidelines are
now published for the use of premix insulin
when initiating, intensifying, or switching
insulin regimens [2, 9, 10].
Compared with basal insulin alone,
initiation with premix insulin has shown
variable results: greater glycemic control in
patients with T2D, but with higher rates of
overall hypoglycemia and weight gain shown
[4, 11–16]. In the 3-year follow-up of the ‘4T’
trial [NCT00184600], similar median HbA1c
levels were achieved, with a lower
hypoglycemia rate seen in the basal insulin
detemir group [17]. For insulin intensification, a
recent meta-analysis reported a small,
non-significant difference for HbA1c reduction
favoring basal–bolus compared with premix,
along with no significant differences in overall
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hypoglycemia, weight gain, and insulin dose
[18]. Broad advantages of premix insulin for
patients diagnosed with T2D include
convenience, improved PPG control compared
with basal insulin alone, a single delivery
device, and the ability to intensify treatment
up to TID if needed [19]. One current practical
guidance suggests that premix should be
considered for, among other factors, initiation
in patients who have a PPG increment of
[3 mmol/L and predictable lifestyle and meal
patterns [10]. For intensification, it is
recommended that premix regimens should be
considered in patients who prefer fewer
injections, less frequent self-monitoring of
blood glucose, and who may have a
diminished ability to inject (e.g., poor manual
dexterity) [10].
Recent years have seen an increase in the
popularity of the basal plus regimen, i.e., when
1–2 injections of prandial insulin are added
prior to the meal(s) associated with the largest
PPG excursion [20], which is the first part of
stepwise intensification toward the full
basal–bolus regimen [3]. An advantage of the
basal plus regimen is that it has greater
flexibility compared with a premix regimen,
but it does require potentially greater
complexity as the insulin regimen intensifies
over time. For example, it requires the patient to
manage two different insulins and injecting
devices, and the demands of variable dosing of
the short-acting ‘plus’ component according to
the carbohydrate content of meals.
Nevertheless, the basal plus approach is now
being used as a therapeutic alternative to
premix BID regimens and is useful to prepare
the patient for a full basal–bolus regimen, in
those who are comfortable with more frequent
injections and the need for increased
self-monitoring [10, 11]. The next
intensification step after basal failure (stepwise
addition of prandial insulin from basal plus to
TID), has shown non-inferiority to a full
basal–bolus regimen for reducing HbA1c with
similar, or lower, rates of hypoglycemia, and
similar weight gain [21, 22].
There are a number of existing trials and
reviews that have compared premix insulin to a
full basal–bolus regimen in patients with T2D
[18, 23–26]. However, there is a gap in the
literature regarding comparison of the efficacy
and safety of basal plus in relation to premix OD
and BID regimens in two commonly
encountered clinical contexts: (1) insulin
initiation in insulin-naı¨ve patients following
the failure of lifestyle modification and OADs to
achieve target HbA1c; (2) insulin intensification
in the context of suboptimal glycemic control,
despite adequately titrated basal insulin.
Insulin treatment is conducted in both
specialist and primary care settings, with the
majority of insulin now being initiated in
primary care [24, 27]. Consequently, a review
of the available evidence comparing the efficacy
and safety of basal plus vs. premix regimens in
patients diagnosed with T2D is relevant to the
broad audience of healthcare professionals
involved in the treatment of such patients.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




At the time of writing, two clinical trials
(n = 1505) have been published that directly
compared basal plus and premix regimens in
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insulin-naı¨ve patients [9, 28]. Both trials were
sponsored by Sanofi and recruited patients with
T2D who had HbA1c [7% ([53 mmol/mol)
despite at least 3 months of OAD use and
lifestyle modification (Table 1). The
GALAPAGOS trial [NCT01121835] included a
2-week screening period, in which patients
continued on their existing therapy, including
diet, exercise, and stable dose of OADs.
Following randomization, patients who started
with insulin glargine OD or premix OD
continued to take metformin, sulfonylureas,
glinides, or dipeptidyl peptidase-4 (DPP-4)
inhibitors, and any other diabetes treatments,
including thiazolidinediones and a-glucosidase
inhibitors, were discontinued at this time.
Patients who started with or switched to two
injections discontinued use of sulfonylureas,
glinides, or DPP-4 inhibitors, with metformin
therapy remaining unchanged [28]. The second
trial by Riddle et al. [9] [NCT00384085]
included a 4-week run-in period, in which
patients continued existing OADs and replaced
insulin secretagogues with an equivalent dose
of glimepiride, along with reducing
pioglitazone dose to 30 mg/day.
HbA1c
In the GALAPAGOS study, 42.5% of patients in
the insulin glargine arm were receiving a basal
plus strategy (insulin glargine OD ? insulin
glulisine OD) by the end of trial (the
remaining 57.5% staying on insulin glargine
OD), while 63.5% received premix BID (the
remaining 36.5% receiving premix OD) [28].
With regard to HbA1c, there was a significantly
greater reduction from baseline in HbA1c
(P\0.01) with premix (OD or BID) compared
with the insulin glargine OD ± insulin glulisine
OD arm. In addition, more patients achieved
HbA1c\7% (\53 mmol/mol) (P\0.01) in the
premix (OD or BID) group compared with
insulin glargine OD ± insulin glulisine OD
[28]. In the Riddle et al. [9] trial,
non-inferiority was reported for a basal plus
regimen (insulin glargine OD ± insulin glulisine
OD) in reducing HbA1c from baseline compared
with a premix BID regimen, and there was no
difference between the regimens in the
proportion of patients achieving HbA1c \7%
(\53 mmol/mol).
Insulin Dose and Body Weight
In the GALAPAGOS study, overall insulin dose
at end of trial was 0.47 U/kg (36.1 U) in the
insulin glargine OD ± insulin glulisine OD arm
and 0.61 U/kg (47.2 U) for those treated with a
premix (OD or BID) regimen [28]. Riddle et al.
[9] reported similar mean weight-adjusted
insulin doses in both regimens at end of trial:
0.92 ± 0.47 U/kg/day and 1.04 ± 0.66 U/kg/day
in the basal plus and premix regimens,
respectively. Unadjusted daily doses at trial
endpoint were 93 ± 54.1 U/day and
110 ± 82.3 U/day in the basal plus and premix
regimens, respectively [9]. Both trials reported
similar weight gain in the respective treatment
arms following insulin initiation [9, 28].
Blood Glucose
Fasting plasma glucose (FPG) was 6.0 mmol/L at
the end of treatment in the insulin glargine
OD ± insulin glulisine OD arm and 6.3 mmol/L
in the premix (OD or BID) arm in the
GALAPAGOS study [28]. The least squares
mean change in FPG from baseline was greater
with insulin glargine OD ± insulin glulisine OD
when compared with premix (OD or BID)
(-0.3 mmol/L; 95% confidence interval [CI]:
-0.5; -0.2; P\0.001) and the mean daily BG
reduction was significantly greater with the
premix (OD or BID) regimen (P = 0.024) [28].
In the Riddle et al. [9] trial, mean FPG at end of
trial (or last observation carried forward) was
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lower with a basal-plus regimen than with
premix BID (6.7 vs. 7.9 mmol/L; P\0.01).
Safety
The GALAPAGOS study reported a significantly
lower incidence of overall symptomatic
hypoglycemia with insulin glargine
OD± insulin glulisine OD when compared with
premix (OD or BID) (B3.1 mmol/L: 1.20 vs. 2.93
events/patient-year; P\0.01, respectively)
(B3.9 mmol/L: 4.85 vs. 8.37 events/patient-year;
P\0.01, respectively) [28]. The significantly
lower rate of hypoglycemia with insulin
glargine OD± insulin glulisine OD compared
with premix (OD or BID) was also observed for
nocturnal symptomatic hypoglycemia
(B3.1 mmol/L: 0.35 vs. 1.03 events/patient-year;
P\0.01, respectively) (B3.9 mmol/L: 1.14 vs.
2.28 events/patient-year; P\0.01, respectively)
[28]. Similarly, Riddle et al. [9] showed a
significantly lower incidence of symptomatic
hypoglycemia with a basal plus regimen when
compared with a premix regimen (\2.8 mmol/L:
0.8 vs. 1.9 events/patient-year; P\0.01,
respectively) (\3.9 mmol/L: 7.1 vs. 12.2
events/patient-year; P\0.01, respectively).
Severe hypoglycemia was similar in both basal
plus and premix regimens (0.1 vs. 0.2
events/patient-year; respectively).
Other adverse events (AEs) or
treatment-emergent adverse events (TEAEs) did
not differ greatly between treatments in either
trial [9, 28]. A similar percentage of patients
treated with insulin glargine OD ± insulin
glulisine OD or premix (OD or BID)
experienced at least one TEAE (34.6% vs.
35.7%) in the GALAPAGOS study; serious
TEAEs were reported in 2.6% of the basal plus
group and 5.0% of the premix group. One fatal
TEAE (pulmonary embolism) occurred in the
basal plus group [28]. The Riddle et al. [9] trial
observed AEs in 79% and 80% of patients in the
premixed and basal plus insulin regimens,
respectively, and serious AEs were reported in
10.8% of the premix group and 12.4% of the
basal plus group. AEs related to the study drug
were not distinguished.
Insulin Intensification
Three published trials (n = 970) have directly
compared basal plus and premix regimens in
patients with T2D uncontrolled with basal
insulin OD plus OADs [29–31] (Table 2).
Sponsored by Sanofi, Jin et al. [29]
[NCT01212913] had an initial 12-week period
whereby insulin was titrated to stabilize insulin
doses in both treatment arms, resulting in
insulin doses being similar in both arms from
week 12 onwards. Sponsored by Eli Lilly,
patients in the Tinahones et al. [30] trial
[NCT01175824] underwent a 2-week screening
period, after which they were randomized to
treatment. Patients continued taking
metformin and/or pioglitazone throughout,
unless changes arising from safety concerns
were required. In the LanScape study
[NCT00965549], sponsored by Sanofi, patients
were randomized only if they had HbA1c[7%
([53 mmol/mol) and a mean self-monitored
FPG of \7 mmol/L following an initial 8- or
12-week run-in period of basal insulin
optimization [31].
HbA1c
Jin et al. assessed intensification with basal plus
(insulin glargine OD ? insulin glulisine [OD or
BID]) and premix BID in Korean patients with
T2D [29]. This study is of interest as there may
be differences in the general context of the
typically high-carbohydrate diet and known
insulin secretory deficits that characterize
Asian T2D [32]. Prandial insulin glulisine was
administered OD in 50% of patients and BID in
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the remaining 50%. With regard to HbA1c,
similar reductions from baseline were observed
in both insulin glargine OD ? insulin glulisine
(OD or BID) and premix BID regimens, along
with the proportion of patients achieving
HbA1c\7% (\53 mmol/mol) [29].
Tinahones et al. [30] observed a greater
reduction in HbA1c for a premix BID regimen
compared with basal plus (insulin glargine
OD ? insulin lispro OD) (P\0.05). However,
there was no difference between the regimens
in the proportion of patients achieving HbA1c
\7% (\53 mmol/mol) [30]. A similar pattern
was seen in the LanScape study, with no
significant differences observed between a
basal plus (insulin glargine OD ? insulin
glulisine OD) and premix BID regimen in
reduction in HbA1c and proportion of patients
achieving HbA1c\7% (\53 mmol/mol) [31].
Insulin Dose and Body Weight
A lower daily insulin dose in the premix BID
arm compared with the basal plus arm was
initially observed in the Jin et al. [29] trial, but
this was gradually up-titrated, such that end of
trial insulin dose was similar in both regimens.
Tinahones et al. [30] did not report a significant
difference in mean insulin dose at end of trial
between basal plus and premix regimens (50.8
vs. 53.1 U, respectively). In the LanScape study,
total daily insulin dose increased from baseline
to end of trial in both basal plus and premix
regimens (?25.5 vs. ?35.6 U, respectively) [31].
For all three insulin intensification trials, weight
gain was similar in both basal plus and premix
BID regimens, with no clinically relevant
differences being observed [29–31].
Blood Glucose
Jin et al. [29] reported that the mean increase in
FPG was lower in the insulin glargine
OD ? insulin glulisine (OD or BID) regimen
when compared with premix BID (3.1 mg/dL vs.
24.4 mg/dL; P\0.01, respectively). The
seven-point self-measured blood glucose
(SMBG) profile change from baseline was
significantly lower in the insulin glargine
OD ? insulin glulisine (OD or BID) arm when
compared with premix BID before breakfast
(-4.27 mg/dL vs. 16.24 mg/dL; P\0.01,
respectively) and 2 h after lunch (-59.42 mg/
dL vs. 32.0 mg/dL; P\0.01, respectively).
Tinahones et al. (2014) reported that change
in FPG from baseline was similar in both the
basal plus and premix BID regimen (0.75 mmol/L
vs. 0.89 mmol/L, respectively), while in a
7-point SMBG curve at end of trial, blood
glucose was significantly lower in the
basal plus regimen before breakfast
(6.26 mmol/L vs. 6.60 mmol/L; P\0.01) and
lower in the premix BID group before lunch
(6.82 mmol/L vs. 7.44 mmol/L; P\0.001)
[30]. The LanScape study did not report
blood glucose outcomes for the treatment
period [31].
Patient-Reported Outcomes
Both the Tinahones et al. trial and LanScape
study included patient-reported outcomes
following treatment [30, 31]. Tinahones et al.
[30] reported no significant difference between
regimens for patient-reported treatment
satisfaction, along with the perceived
emotional and physical effects of treatment.
The LanScape study, however, reported
significant differences in favor of basal plus for
total treatment satisfaction, total insulin
satisfaction, present quality of life (QoL), and
perceived frequency of hyperglycemia.
However, no significant differences between
the groups were observed for the perceived
frequency of hypoglycemia, change in the
average weighted impact of diabetes on QoL,
or health status [31].
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Safety
Jin et al. reported that, for weeks 0–12, incidence
of overall hypoglycemia was higher in the
insulin glargine OD? insulin glulisine (OD or
BID) arm compared with premix BID (818 events
vs. 375 events; P\0.05, respectively). For
weeks 12–24, the rate of overall hypoglycemia
was 152 vs. 386 (P = 0.23) events for insulin
glargine OD? insulin glulisine (OD or BID) and
premix BID regimens, respectively. Statistical
differences in the rate of nocturnal
hypoglycemia in the insulin glargine
OD? insulin glulisine (OD or BID) and premix
BID regimens were not observed for weeks 0–12
(86 vs. 61 events, respectively; P = 0.11) and
weeks 12–24 (22 vs. 57 events, respectively;
P = 0.67), along with severe hypoglycemia:
weeks 0–12 (1 vs. 0 events, respectively;
P = 0.49) and weeks 12–24 (one event for each;
P = 0.74) [29].
Tinahones et al. [30] reported similar rates of
overall hypoglycemia in both basal plus and
premix BID regimens (B3.9 mmol/L: 16.5 vs. 13
events/patients-year, respectively), along with
nocturnal hypoglycemia (B3.9 mmol/L: 1.8 vs.
1.5 events/patients-year, respectively). No severe
hypoglycemia was observed in either treatment
arm. No significant difference between basal plus
and premix regimens in overall confirmed
hypoglycemia (estimated rate ratio [RR]: 0.84;
95% CI: 0.64;1.11; P = not significant [NS]) was
observed in the LanScape study [31]. Nocturnal
hypoglycemia was significantly lower in the
premix group (RR: 1.57; 95% CI: 1.08;2.29;
P\0.05), and severe hypoglycemia occurred in
13 (7.6%) basal plus patients and in nine (5.5%)
premix patients [31].
As with insulin-naı¨ve patients, there were
similar numbers of TEAEs between the two
intensification regimens. Of the 107 AEs
reported in the Jin et al. [29] trial, one AE was
judged to be related to insulin glargine
OD ? insulin glulisine (OD or BID) treatment
and four to premix BID treatment (no further
details regarding the type of AEs are reported).
In Tinahones et al. [30], 2.9% of basal plus
patients and 3.8% of premix users experienced
AEs considered to be possibly related to study
treatment; overall serious TEAEs were reported
by 3.3% and 4.7% of patients receiving basal
plus and premix insulin, respectively. The
proportion of patients experiencing overall
TEAEs in the LanScape study was 75.3% in the
basal plus and 65.9% in the premix BID insulin
arm, with the majority of TEAEs being mild.
One participant died in each treatment arm;
however, neither death was considered to be
due to the study treatment [31].
DISCUSSION
Insulin Initiation in Insulin-Naı¨ve Patients
Broadly, in clinical practice, the selection of
suitable therapy following failure of OADs and
lifestyle modification can be a difficult decision
for many clinicians. Although basal insulin is a
common first insulin regimen, there are a subset
of patients for whom postprandial rises are
significant and for whom clinicians may
reasonably consider a basal plus or premix
regimen from the outset.
With regard to the reviewed trials, as would
be expected, HbA1c reductions were greater in
insulin-naı¨ve patients exposed to insulin for the
first time [9, 28], compared to those undergoing
insulin intensification [29–31]. This is to be
expected, as some of the benefit of insulin
therapy is likely to have already been derived by
the group on insulin as opposed to the
insulin-naı¨ve cohort.
For the trials assessing insulin initiation,
both premix (OD or BID) and basal plus
treatment resulted in a reduction in HbA1c
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from baseline, in patients who had failed on
lifestyle modification and OAD treatment
[9, 28]. A higher proportion of patients
achieved HbA1c \7% (\53 mmol/mol) with
premix insulin in both trials, and the
GALAPAGOS study reported a significantly
greater reduction in HbA1c in premix (OD or
BID) insulin compared with insulin glargine
OD ± insulin glulisine OD treatment [28].
However, it is possible that the degree of
HbA1c lowering was related to the higher total
daily dose of premix insulin in individuals,
rather than the type of insulin itself.
Both trials reported significantly greater
hypoglycemia and numerically higher,
although not statistically significant, weight
gain with the use of premix [9, 28]. Indeed,
the greatest weight gain following insulin
initiation was the 6.9 kg observed in the
premix BID arm of Riddle et al. [9], compared
with a 5.2 kg increase in the basal plus arm. This
greater weight gain is likely to be due to the fact
that patients in this trial had the highest
starting FPG, HbA1c, and insulin doses, and
the trial had the longest duration compared
with the other trials reviewed here. No clinically
significant differences in TEAEs were observed
between treatments in either of the insulin
initiation trials [9, 28].
In summary, the two reviewed trials report
greater HbA1c reductions with premix
regimens, but less favorable hypoglycemia
profiles and weight gain compared with basal
plus, and it is possible that these differences
could be a reflection of the level of insulin
dosing rather than the regimen itself (Table 3).
Insulin Intensification from Basal Insulin
For insulin intensification, the three published
trials indicate that intensification from basal
insulin OD ± OADs with either basal plus or
premix BID resulted in similar reductions in
HbA1c, along with similar proportions of
patients achieving HbA1c \7%
(\53 mmol/mol) [29–31].
Tinahones et al. [30] indicated a significant
advantage for the premix BID regimen in mean
HbA1c reduction in the context of significantly
greater weight gain, although it can be argued
that the increase of around 0.6 kg evident with
premix relative to basal plus is unlikely to be
clinically significant. The premix BID arm of
Tinahones et al. also reported the highest
proportion of patients (34.5%) achieving
HbA1c \7% (\53 mmol/mol) compared with
the premix BID arm in the other two trials
[29–31]. However, in secondary analysis, the
proportion of patients achieving HbA1c \7%
(\53 mmol/mol) in the premix BID arm was not
statistically greater than the basal plus arm of
the trial [29–31].
Rates of overall hypoglycemia were similar in
both regimens across the three trials [29–31].
However, nocturnal hypoglycemia was
significantly higher in the basal plus arm
compared with the premix arm of the
LanScape study [31], which may be
attributable to the evening prandial insulin
dose in the basal plus arm being titrated to a
tight PPG target when compared with the
premix group in which only preprandial blood
glucose was targeted. Rates of severe
hypoglycemia were also similar in both
regimens across the three trials [29–31], with,
again, the highest rates being observed in the
LanScape study. The relatively high rates of
severe hypoglycemia in the LanScape study may
be partly attributable to the high incidence of
accidental overdose observed in the basal plus
arm of this trial [31]. Additionally, a result of
note from the Jin et al. trial is the lower
hypoglycemia observed in the first 12 weeks of
premix BID treatment when compared with









































































































































































































































































































































































































































































































Diabetes Ther (2016) 7:641–657 651
basal plus, with similar reductions in HbA1c.
For clinicians, this finding could be argued to
suggest that premix BID therapy that starts with
a lower insulin dose (i.e., 6 U BID)—which is
then gradually increased—may have benefits in
terms of safety (Table 4).
With regard topatient-reportedoutcomes, one
trial showed greater benefits with basal plus
compared with premix in overall satisfaction
with treatment, satisfaction with insulin,
perceived frequency of hyperglycemia, and
overall present QoL [31]. Broadly, this could be
argued to partiallymirror the previously observed
increase in patient satisfaction with basal plus
relative to a full basal–bolus regimen previously
observed in theNovoNordisk-sponsoredFullSTEP
study [NCT01165684] [22], while recognizing
that the trial of Tinahones et al. did not observe
significant differences in these patient-reported
outcomes between the basal plus and premix
regimens.
Overall, the three intensification trials
reported modest weight gains of 0.5–2.5 kg
over 24 weeks [29–31]. As with the insulin
initiation trials, no clinically significant
differences in TEAEs were observed between
treatments [9, 28–31].
When considering the three insulin
intensification trials together, it is important
to note that the proportion of patients
achieving HbA1c \7% (\53 mmol/mol)
following intensification with basal plus or
premix BID treatment was low (20.6–34.5%)
[29–31], compared with the 63.5% observed
with a full basal–bolus regimen [33]. As such,
within the context of clinical guidelines, it is
likely that the majority of the patients included
in the current review would eventually need
further intensification of their insulin regimen
with the addition of further daily injections
[3, 34], while recognizing that a reduction in
insulin treatment can be achieved if other
factors improve (i.e., lifestyle modification)
[3, 24]. Further work is required to identify
any specific characteristics that can identify
potential non-responders to insulin
intensification with either basal plus or premix
regimens [11], and whether adding a further
dose of insulin would significantly improve
glycemic control in these patients, compared
with the addition of alternative treatments (e.g.,
glucagon-like peptide-1 receptor agonists
[GLP-1RAs], sodium–glucose co-transporter-2
[SGLT2] inhibitors and DPP-4 inhibitors)
[3, 35, 36].
Strengths and Weaknesses
Strengths of the reviewed trials included the
multinational design of the majority of the
trials, which improves the overall
generalizability of the results. Furthermore, the
majority of intensification trials had either a
run-in or selection criteria that ensured that
patients had inadequate glycemic control
despite good FPG control, suggesting the need
to intensify therapy to target PPG. The patient
sample also had a relatively long duration of
diabetes, which mimics the delay in insulin
initiation and intensification often witnessed in
real-world clinical practice [37, 38].
With regard to weaknesses, all trials were
open-label, and only two trials used a central
laboratory measurement for HbA1c. There was
also some heterogeneity observed in the patient
sample; for instance, the Jin et al. trial recruited
Korean patients diagnosed with T2D with a
markedly lower body mass index and longer
duration of illness compared to the other
insulin intensification trials [29–31]. There
were also differences in the primary endpoints
used and the type and dose of OADs, along with
the premix regimens (i.e., both OD and BID
regimens being included). The use of premix
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TID was also not assessed, which has previously
shown non-inferiority to a full basal–bolus
regimen for glycemic control [25].
Additionally, there were differences observed
with regard to the basal plus algorithms
employed, with Jin et al. [29] including
prandial insulin OD and BID within their basal
plus arm and the GALAPAGOS study including
prandial insulin OD as part of a larger,
basal-only OD arm [28]. All of the trials were
sponsored by pharmaceutical companies,
although the authors maintained final
responsibility for the publications.
Differences in titration algorithms and
hypoglycemia definitions were also observed
and, therefore, when interpreting the data, it is
important to consider that differences in
hypoglycemia rates seen across the trials were
likely to have been driven not just by insulin type
and doses, but also by the study titration strategy
and co-administration of insulin secretogogues. It
is also likely that hypoglycemia rates will be lower
the earlier insulin therapy is commenced (i.e., at a
shorter duration of T2D than in the included
trials) due to preservation of counter-regulatory
responses toglucose lowering. Thedurationof the
included trials was also relatively short, with the
longest trial showing a high rate of attrition [9].
For the current review, a measure of
statistical heterogeneity and quality
assessment would have been of interest, and
would have improved the methodological
quality. Moreover, combination therapy with
newer agents (e.g., GLP-1RAs, SGLT2 inhibitors)
was not studied, but is relevant to clinical
decision-making when considering treatment
options for patients with T2D.
CONCLUSION
The current review indicates that the
similarities between basal plus and premix
(OD and BID) regimens when either initiating
or intensifying insulin treatment could be
argued to be generally greater than the
differences, and superiority in one area may be
at the cost of increased AEs (e.g., greater HbA1c
reduction with increased hypoglycemia).
However, it is important to note that
hypoglycemia and weight gain arising from
the regimens included in the current review
may be lower than is commonly feared by
patients, and this ‘psychological insulin
resistance’ often contributes to a delay in
insulin initiation and intensification [37, 39].
When initiating and intensifying insulin
treatment, guidelines from bodies such as the
ADS and the IDF recommend that clinicians use
discretion and a patient-centered approach to
treatment [2, 3]. Indeed, when considering that
the results of the current review suggest that
both basal plus and premix regimens have
comparable efficacy and safety in both insulin
initiation and intensification contexts, the
patient-centered approach becomes of
heightened importance within T2D treatment.
Patient preference and QoL outcomes should be
considered and include elements not assessed in
the current review, such as patients’ lifestyle
(e.g., hours of work) and dietary habits. For
instance, a premix regimen may be more
suitable for patients with regular meals and a
large, consistent carbohydrate intake.
Additionally, a basal plus regimen may be
more appropriate for patients with a more
varied meal and activity pattern. Moreover,
factors such as patients’ health literacy and
ability to manage two different insulins in a
basal plus regimen vs. one pen in a premix
regimen, overall hypoglycemia risk, likely
adherence to insulin therapy, and available
healthcare resources should be considered
[2, 3, 11]. It should also be considered that
premixed insulins need to be adequately mixed
654 Diabetes Ther (2016) 7:641–657
or gently shaken by patients to ensure safety of
administration and dose.
However, while recognizing these factors,
the current review suggests that both basal plus
and premix insulin regimens remain, and are
likely to continue being, relatively efficacious
and safe options for patients with T2D.
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